Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). However, challenges remain including long manufacturing processes that need to be overcome. We presented the CD19-targeting CAR-T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cheng, He, Jiaping, Liu, Li, Wang, Jishi, Wang, Sanbin, Liu, Ligen, Ge, Jian, Gao, Lei, Gao, Li, Kong, Peiyan, Liu, Yao, Liu, Jia, Han, Yu, Zhang, Yongliang, Sun, Zhe, Ye, Xun, Yin, Wenjie, Sersch, Martina, Shen, Lianjun, Cao, Wei William, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232607/
https://www.ncbi.nlm.nih.gov/pubmed/35750687
http://dx.doi.org/10.1038/s41408-022-00688-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232607/
https://www.ncbi.nlm.nih.gov/pubmed/35750687
http://dx.doi.org/10.1038/s41408-022-00688-4

Ejemplares similares